TGFB1 and neoplasm: The development of T cells armed with a dominant negative TGF-beta receptor (a human TGF-β receptor with a truncated endodomain) has conferred tumor-derived TGF-β resistance to antigen-specific cytotoxic T lymphocytes (CTLs) [88].